OBJECTIVES: We aimed to determine whether the common variation at the chromogranin A (CHGA) locus increases susceptibility to hypertension. BACKGROUND: CHGA regulates catecholamine storage and release. Previously we systematically identified genetic variants across CHGA. METHODS: We carried out dense genotyping across the CHGA locus in >1,000 individuals with the most extreme blood pressures (BPs) in the population, as well as twin pairs with autonomic phenotypes. We also characterized the function of a trait-associated 3'-untranslated region (3'-UTR) variant with transfected CHGA 3'-UTR/luciferase reporter plasmids. RESULTS: CHGA was overexpressed in patients with hypertension, especially hypertensive men, and CHGA predicted catecholamines. In individuals with extreme BPs, CHGA genetic variants predicted BP, especially in men, with a peak association occurring in the 3'-UTR at C+87T, accounting for up to approximately 12/ approximately 9 mm Hg. The C+87T genotype predicted CHGA secretion in vivo, with the +87T allele (associated with lower BP) also diminishing plasma CHGA by approximately 10%. The C+87T 3'-UTR variant also predicted the BP response to environmental (cold) stress; the same allele (+87T) that diminished basal BP in the population also decreased the systolic BP response to stress by approximately 12 mm Hg, and the response was smaller in women (by approximately 6 mm Hg). In a chromaffin cell-transfected CHGA 3'-UTR/luciferase reporter plasmid, the +87T allele associated with lower BP also decreased reporter expression by approximately 30%. In cultured chromaffin cells, reducing endogenous CHGA expression by small interfering ribonucleic acid caused approximately two-thirds depletion of catecholamine storage vesicles. CONCLUSIONS: Common variant C+87T in the CHGA 3'-UTR is a functional polymorphism causally associated with hypertension especially in men of the population, and we propose steps ("intermediate phenotypes") whereby in a sex-dependent fashion this genetic variant influences the ultimate disease trait. These observations suggest new molecular strategies to probe the pathophysiology, risk, and rational treatment of hypertension.
OBJECTIVES: We aimed to determine whether the common variation at the chromogranin A (CHGA) locus increases susceptibility to hypertension. BACKGROUND:CHGA regulates catecholamine storage and release. Previously we systematically identified genetic variants across CHGA. METHODS: We carried out dense genotyping across the CHGA locus in >1,000 individuals with the most extreme blood pressures (BPs) in the population, as well as twin pairs with autonomic phenotypes. We also characterized the function of a trait-associated 3'-untranslated region (3'-UTR) variant with transfected CHGA 3'-UTR/luciferase reporter plasmids. RESULTS:CHGA was overexpressed in patients with hypertension, especially hypertensivemen, and CHGA predicted catecholamines. In individuals with extreme BPs, CHGA genetic variants predicted BP, especially in men, with a peak association occurring in the 3'-UTR at C+87T, accounting for up to approximately 12/ approximately 9 mm Hg. The C+87T genotype predicted CHGA secretion in vivo, with the +87T allele (associated with lower BP) also diminishing plasma CHGA by approximately 10%. The C+87T 3'-UTR variant also predicted the BP response to environmental (cold) stress; the same allele (+87T) that diminished basal BP in the population also decreased the systolic BP response to stress by approximately 12 mm Hg, and the response was smaller in women (by approximately 6 mm Hg). In a chromaffin cell-transfected CHGA 3'-UTR/luciferase reporter plasmid, the +87T allele associated with lower BP also decreased reporter expression by approximately 30%. In cultured chromaffin cells, reducing endogenous CHGA expression by small interfering ribonucleic acid caused approximately two-thirds depletion of catecholamine storage vesicles. CONCLUSIONS: Common variant C+87T in the CHGA 3'-UTR is a functional polymorphism causally associated with hypertension especially in men of the population, and we propose steps ("intermediate phenotypes") whereby in a sex-dependent fashion this genetic variant influences the ultimate disease trait. These observations suggest new molecular strategies to probe the pathophysiology, risk, and rational treatment of hypertension.
Authors: D T O'Connor; P A Insel; M G Ziegler; V Y Hook; D W Smith; B A Hamilton; P W Taylor; R J Parmer Journal: Curr Hypertens Rep Date: 2000-02 Impact factor: 5.369
Authors: Harold Snieder; Gregory A Harshfield; Paule Barbeau; David M Pollock; Jennifer S Pollock; Frank A Treiber Journal: Biol Psychol Date: 2002-10 Impact factor: 3.251
Authors: M A Takiyyuddin; J H Cervenka; P A Sullivan; M R Pandian; R J Parmer; J A Barbosa; D T O'Connor Journal: Circulation Date: 1990-01 Impact factor: 29.690
Authors: V Herrmann; R Büscher; M M Go; K M Ring; J K Hofer; M T Kailasam; D T O'Connor; R J Parmer; P A Insel Journal: Am J Hypertens Date: 2000-09 Impact factor: 2.689
Authors: Kuixing Zhang; Saiful A Mir; C Makena Hightower; Jose Pablo Miramontes-Gonzalez; Adam X Maihofer; Yuqing Chen; Sushil K Mahata; Caroline M Nievergelt; Nicholas J Schork; Barry I Freedman; Sucheta M Vaingankar; Daniel T O'Connor Journal: J Am Soc Nephrol Date: 2014-11-12 Impact factor: 10.121
Authors: Jiaur R Gayen; Kuixing Zhang; Satish P RamachandraRao; Manjula Mahata; Yuqing Chen; Hyung-Suk Kim; Robert K Naviaux; Kumar Sharma; Sushil K Mahata; Daniel T O'Connor Journal: Circ Cardiovasc Genet Date: 2010-08-20
Authors: Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton Journal: Endocr Rev Date: 2011-08-23 Impact factor: 19.871
Authors: Ryan S Friese; Jiaur R Gayen; Nitish R Mahapatra; Geert W Schmid-Schönbein; Daniel T O'Connor; Sushil K Mahata Journal: Physiol Genomics Date: 2009-12-01 Impact factor: 3.107
Authors: Lei Wang; Fangwen Rao; Kuixing Zhang; Manjula Mahata; Juan L Rodriguez-Flores; Maple M Fung; Jill Waalen; Myles G Cockburn; Bruce A Hamilton; Sushil K Mahata; Daniel T O'Connor Journal: J Am Coll Cardiol Date: 2009-09-01 Impact factor: 24.094